Rita Nanda, MD, specializes in the treatment of all forms of breast cancer. Dr. Nanda’s practice focuses on women with triple-negative, hereditary, locally advanced and metastatic breast cancers. She is a strong advocate of using chemotherapy prior to surgery (neoadjuvant chemotherapy) to better understand how an individual's tumor responds to therapy, so that treatment can be tailored to each patient's unique case.
Dr. Nanda’s research interests include identifying new and better treatments for the management of breast cancer. She leads the UChicago Medicines breast cancer clinical trial program. She has extensive knowledge of clinical trials and new therapies in development for all forms of advanced breast cancer. She serves as a principal investigator for the Translational Breast Cancer Research Consortium (TBCRC) and the I-SPY 2 Clinical Trial Network.
Dr. Nanda’s research has been funded by the National Institutes of Health (NIH), the Department of Defense Breast Cancer Research Program, the Doris Duke Charitable Foundation, the Susan G. Komen Foundation, and the Metastatic Breast Cancer Network. She currently serves as a co-principal investigator on the University of Chicago’s Interdisciplinary Cancer Health Disparities P20 SPORE.
Dr. Nanda’s research interests include identifying new and better treatments for the management of breast cancer. She leads the UChicago Medicines breast cancer clinical trial program. She has extensive knowledge of clinical trials and new therapies in development for all forms of advanced breast cancer. She serves as a principal investigator for the Translational Breast Cancer Research Consortium (TBCRC) and the I-SPY 2 Clinical Trial Network.
Dr. Nanda’s research has been funded by the National Institutes of Health (NIH), the Department of Defense Breast Cancer Research Program, the Doris Duke Charitable Foundation, the Susan G. Komen Foundation, and the Metastatic Breast Cancer Network. She currently serves as a co-principal investigator on the University of Chicago’s Interdisciplinary Cancer Health Disparities P20 SPORE.
Specialties
Areas of Expertise
Board Certifications
- Medical Oncology
Memberships & Medical Societies
- American Association for Cancer Research
- Society for Immunotherapy of Cancer
- American Society of Clinical Oncology
Practicing Since
- 2005
Languages Spoken
- English
Medical Education
- University of Chicago Pritzker School of Medicine
Residency
- University of Chicago Medicine
Fellowship
- University of Chicago Medicine
News & Research
View Published Papers- Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer
- Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
- Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
- Olaparib In Metastatic Breast Cancer
- Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
- A Safety Study of SGN-LIV1A in Breast Cancer Patients
- Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
- Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
- Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- A Study in Patients With Advanced Breast Cancer
- Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
- Futibatinib in Patients With Specific FGFR Aberrations
- A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
- Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
- Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
- Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
- The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
- OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
- Lapatinib and Trastuzumab With or Without Endocrine Therapy
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
- Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
- A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
- Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
- Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer
- Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
- Male Breast Cancer: Understanding the Biology for Improved Patient Care
- Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
- Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)
- Endocrine Response in Women With Invasive Lobular Breast Cancer
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer
- A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
- Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
- Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
- T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient
